FSD Pharma Inc FSDDF announced this week it closed a deal to acquire Prismic Pharmaceuticals, a U.S.-based specialty pharmaceutical company dedicated to addressing the opioid crisis.
Through the utilization of its micro-PEA platform, the company seeks to develop novel, non-addictive prescription drugs. Such formulations impact the endocannabinoid system. This means that lower doses of drugs can be used to achieve the desired therapeutic effect.
FSD is focused on the research and development of synthetic cannabinoid treatments for CNS disorders.
Need more cannabis news? Check out all of our coverage here.
Commenting on the purchase, FSD Pharma’s CEO Raza Bokhari told Benzinga:
“The Prismic Pharmaceuticals acquisition demonstrates the strategic depth in our vision for FSD Pharma and signals a paradigm shift in the overall outlook of the company. FSD Pharma can now embark upon R&D of drugs through the various stages of the FDA approval process, with the goal of eventually making synthetic cannabinoid & opioid sparing prescription medications targeting the human endocannibinoid system and make them available for commercial use.”
Related Stories:
Meet The Newest Accelerator For Minority-Owned Cannabis Businesses
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.